Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment

Filanovsky, Kalman; Shvidel, Lev

doi:10.4081/hr.2017.7078

Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Editorial

26 September 2017

1 Page

Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment

and

Department of Hematology, Kaplan Medical Center, Rehovot 76100, Israel

Hadassah and Hebrew University Medical School, Jerusalem P.O. Box 12272, Israel

Author to whom correspondence should be addressed.

Hematol. Rep.2017, 9(3), 7078;https://doi.org/10.4081/hr.2017.7078

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Ibrutinib (Imbruvica) is a first-in-class oral inhibitor of Bruton’s tyrosine kinase (BTK), an essential enzyme in B-cell receptor signaling pathway [...]

Keywords:

lymphoma; ibrutinib; chronic renal failure

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia

Two Cases of Angioimmunoblastic T-Cell Lymphoma with Concomitant Positive Serology for Acute Epstein-Barr Virus Infection